The six pharmaceutical companies will cease listing in 2020

The public is no longer unfamiliar with the board, the opening of the board not only let many investors in the short term large profits, but also to make corporate financing channels more diversified.
As of December 25, 2020, the SSE has received a total of 516 listed enterprises, of which the pharmaceutical industry involves pharmaceutical manufacturing, research and experimental development (mainly CRO enterprises), special equipment manufacturing (mainly refers to medical devices) 3 categories, a total of 106 (second) enterprises were accepted by the SSE.
from its initial structural design point of view, the board is to better help the development of scientific and technological innovation enterprises, promote China's science and technology and comprehensive strength of continuous progress.
the current social capital of the science and technology board platform has overtaken the new three-board platform, the same company in the science and technology board and the new three-board, received two distinct treatment.
at the same time, the board is not want to be able to go on, some enterprises after many rounds of inquiries, they will be overwhelmed with "torture", choose to voluntarily withdraw the application, terminate the listing process.
so far, a total of 62 companies have terminated the listing of the board, of which 6 pharmaceutical companies in 2020 have made the decision to terminate the listing.
are only a brief introduction to the six enterprises that have terminated the pharmaceutical companies listed on the board.
Zhengji Pharmaceutical Co., D.M., was approved by the Shanghai Stock Exchange on December 3rd, using the "Standard 1" declaration and China Merchants Securities as its sponsor.
Zhengji Pharmaceuticals had planned to raise 1,144 million yuan, mainly used in the first phase of the research and development and production project of innovative API and preparations of Sunzhao Zhengji Pharmaceutical Co., Ltd., Suzhou Zhengji Pharmaceutical Research Co., Ltd. research and development center construction projects and supplementary working capital. according to the
prospectus, Zhengji Pharmaceuticals is mainly engaged in the research and development, production and sales of specialty raw materials and advanced intermediates, is a national high-tech enterprise focused on drug innovation structure invention, new technology research and application, specialty drug research and manufacturing, developed for influenza, liver disease, tumor, cardiovascular disease and a series of major diseases of the new drug synthesis process, can provide antiviral, cardiovascular, digestive system and anti-tumor four types of raw materials and intermediates.
is surprising that within 20 days of submitting the listing application and without entering the inquiry stage, Zhengji Pharmaceuticals submitted an application for termination of the listing to the Shanghai Stock Exchange.
December 25, the Shanghai Stock Exchange officially terminated Zhengji Pharmaceuticals' application for the listing of the company's board, which is also the shortest "from submission to termination" period since the opening of the board.
Jianjian Pharmaceuticals is a medical device product and service provider in the field of organ transplantation, which mainly provides equipment for organ preservation, transportation, evaluation and repair in transplantation, medical supplies for transplantation, and in-body diagnostic reagents in the field of transplantation.
main product is LifePort kidney perfusion running box, is a relatively widely used kidney cryogenic mechanical perfusion products.
Jian-Jiang Pharmaceutical Co., Ltd. was accepted on May 11, 2020 and originally planned to raise 1,143 million yuan, mainly for the organ transplant innovation research and development platform project and innovation and development reserve funds, including the acquisition of 31.33 percent of the shares of Shanghai Yuvo.
between June and December, the company was asked four rounds of questions.
't be easy to get through four rounds of inquiry, the board's listing committee announced on December 11th that the 124th Review Conference of 2020 would be reviewed on December 18th.
dramatic reversal took place on the eve of the meeting, and on the evening of December 17th, Jianjin Pharmaceuticals, which was supposed to be reviewed on December 18th, 2020, withdrew its application for listing and Guojin Securities withdrew its sponsorship.
the relevant rules, the Shanghai Stock Exchange has terminated the listing review of the issue of Jianjiang Pharmaceuticals and cancelled the deliberations of the Shanghai Municipal Committee.
Zesheng Technology Zesheng Technology was founded by Dr. Zhou Mingdong, a scientist in the field of cardiomyocyte therapy, and the Shanghai Pudong SASAC holds a total of about 22.73 percent of The company's largest shareholder through the wholi-owned Sun Company Zhang Jiangke Investment and Pudong New Production Investment.
Technology Science and Technology Board IPO application was accepted by SSE Science and Technology Board on June 17 this year.
the company was created by the new three-board transfer section, originally planned to raise 1.5 billion yuan for new drug research and development projects and supplementary working capital.
According to the prospectus, the company focuses on heart failure, digestive system smooth muscle failure, nervous system failure and other major diseases in the field of organ function decline/failure research, the main product pipeline currently has four drugs in the study of 6 projects, the core of which is in the study of the drug Newcastle (injection recombinant Newland Green) is a potential international first innovative drug for the treatment of chronic heart failure (First in Class).
Between July and October, Zesheng Technology received three inquiries from the Shanghai Stock Exchange, the third of which referred to Zesheng Technology's procurement of sodium barbito from Haring, in violation of the Regulations on the Administration of Narcotic Drugs and Psychotic Drugs (State Council Order No. 666), which constituted the procurement of controlled drugs through illegal channels.
the sprint section, the internal turnover of Zesheng Technology is also quite frequent.
Former Vice President of Strategy and New Business Development for The Asia Pacific Product Line of Yangsen Pharmaceuticals, Luo Baoxiong, the executive vice president of Shinzawa Technology, left his post in July this year for personal reasons after joining Zesheng Technology on January 8, 2019.
the company's sales staff also fell sharply from 25 to 0.
December 10, the Shanghai Stock Exchange issued the Decision on Ending the Initial Public Offering of Shares of Zesheng Technology and Reviewing the Listing of the Science and Technology Board.
Sykes Sykes is a high-tech enterprise engaged in the research and development, production and sale of bio-materials-related medical devices, with leading technology in the field of anti-adhesive, interventional embolism and medical sealing, and some products achieve "domestic first" and "import substitution".
's application for listing was accepted by the company on June 30, 2020 and received its first inquiry from the SSE on July 28.
planned to raise 305 million yuan, mainly for biopharmaceutical production and research and development base phase II projects.
September-November, the SSE conducted two rounds of inquiries on Sykes, questioning the authenticity of its revenues, core products, core distributors, related parties and associated transactions, research and development costs, inventory and sales costs.
after two rounds of responses and an update of its half-yearly financial data on November 25, 2020, Sykes filed an application to terminate the listing of the Board with the Shanghai Stock Exchange on December 7 and the SSE agreed to its application for termination on December 8.
Billion Tengjing Ang Teng Jing Ang is a self-research and introduction of new drug development company, is currently in research projects 12, mainly covering breast cancer and stomach cancer and other tumor adaptation.
Company's "fifth set of standards" of the listing application was accepted by the Shanghai Stock Exchange on June 23, 2020, its original plan to raise 1.316 billion yuan, mainly for drug research and development projects and marketing network construction projects.
first inquiry into the company in July, when the company was working on a product pipeline.
September 29, 2020, the financial information recorded by Etenjing Ang has expired and needs to be submitted supplementaryly, and the SSE suspended its listing review in accordance with Article 64 (6) of the Audit Rules.
December 3rd, the SSE terminated its review of Etenjing's listing on the board based on a withdrawal application filed by Eteng Jingang and its sponsor Guotai Junan Securities.
the "first set of standards" of the listing application was accepted by the Shanghai Stock Exchange on June 1 this year, and then entered the state of inquiry on the 30th of the same month.
the company originally planned to raise 1.59 billion yuan, mainly for innovative targeted drugs in the preclinical and clinical stages of research and development and supplementary working capital.
prospectine disclosed that Coffey Ping focused on cardiovascular, digestive system and other major diseases and chronic diseases, the company's actual control of people for Qin Lilin, Yan Peiling (two people have been husband and wife relationship), the total disposable voting rights accounted for 88.54 percent of the company's shares.
's operating income mainly comes from dansan ketone II.A sodium sulfonate injection, the variety in the last 3 years sales accounted for nearly 90% of revenue.
, however, according to the SSE inquiry letter, the registered approval of the sodium sulfonate injection of Dansan ketone II.A is not in Coffeypin.
this is a cooperative variety between the enterprise and Shanghai Shanghai Pharmaceuticals subsidiary Bio-Chemical Pharmaceuticals.
said that "the bio-chemical pharmaceutical industry is responsible for production, Coffey Ping is responsible for the national distribution."
SSE questioned whether it was only a sales or channel company in the light of its own business positioning and main product business model.
from June to October, Mr. Coffey received three rounds on the Shanghai Stock Exchange.
in early November, the company disclosed in the new three board, due to strategic adjustments, the company decided to voluntarily withdraw the filing of the SSE Board application materials.
It is worth mentioning that the termination of the listing application does not mean that enterprises will never have access to the board market, according to the "Kotron board initial public offering stock registration management measures (trial)" and "Kotron board listed companies continue to supervise the measures (trial)", the board was terminated after six months can be reapplied.
such as Hoobo Bio, which ceased the listing of the Board on 6 December 2019, submitted its application for listing on 11 May 2020 and be registered on 15 December 2020.
。